In line with this, an antiproliferative action of CB1 antagonism in thyroid, mantle cell lymphoma, colon and breast cancers [15–20], as well as in adipocyte and in hepatic myofibroblast has been demonstrated [28–31]. This evidence concerns the gene CNR1 and breast carcinoma.